- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01511874
Efficacy and Safety Study of ELIGARD 22.5mg With Prostate Cancer
September 21, 2015 updated by: HanAll BioPharma Co., Ltd.
Non-comparative, Opened Multicenter Study to Assess the Efficacy and Safety of ELIGARD 22.5mg in the Treatment of Subjects With Prostate Cancer
The purpose of this study is to evaluate efficacy and safety of ELIGARD 22.5mg in the treatment of subjects with prostate cancer.
Study Overview
Study Type
Interventional
Enrollment (Actual)
42
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Seoul, Korea, Republic of
- Department of Urology,Yonsei University,College of Medicine, Gangnam Severance Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
20 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Male
Description
Inclusion Criteria:
- Male of 20 years or above
- Subject with prostate cancer with TNM stage T2~4NxMx
- Blood testosterone concentration ≥ 100ng/dl
- Bilirubin ≤ 1.5xULN, transaminase ≤ 2.5xULN
- WHO ECOG performance status ≤ 2
- Signed written informed consent
Exclusion Criteria:
- Hormone-Refractory Prostate cancer
- Brain metastasis
- Another primary malignant tumor except for prostate cancer
- Other conditions which in the opinion of the investigator preclude enrollment into the study
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: ELIGRAD 22.5mg
a subcutaneous injection of ELIGARD 22.5mg at 0 and 12weeks
|
a subcutaneous injection of ELIGARD 22.5mg at 0 and 12weeks
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Ratio of subjects whose blood testosterone concentration is maintained below 50ng/dl at 4 weeks after injection of ELIGARD 22.5mg
Time Frame: 4weeks
|
4weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Ratio of subjects whose blood testosterone concentration is maintained below 50ng/dL until 24weeks
Time Frame: 24weeks
|
24weeks
|
Ratio of subjects whose blood testosterone concentration exceed 50ng/dL until 24weeks
Time Frame: 24weeks
|
24weeks
|
Change in self assessment scale grade
Time Frame: 0,4, 8, 12, 24 weeks
|
0,4, 8, 12, 24 weeks
|
Ratio of subjects whose blood testosterone concentration is below 20ng/dL at 4weeks and 24weeks
Time Frame: 4, 24 weeks
|
4, 24 weeks
|
Change in ECOG performance status
Time Frame: 0,4,8,12, 24weeks
|
0,4,8,12, 24weeks
|
Change in blood prostate-specific antigen
Time Frame: 0,4,8,12,24 weeks
|
0,4,8,12,24 weeks
|
Change in QoL_EPIC grade
Time Frame: 0,12, 24weeks
|
0,12, 24weeks
|
Change in penile length
Time Frame: screening, 12, 24weeks
|
screening, 12, 24weeks
|
Change in testicular volume
Time Frame: screening, 12, 24weeks
|
screening, 12, 24weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Byung Ha Chung, Medicine, Department of Urology,Yonsei University,College of Medicine, Gangnam Severance Hospital
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
January 1, 2011
Primary Completion (Actual)
May 1, 2013
Study Completion (Actual)
December 1, 2013
Study Registration Dates
First Submitted
January 13, 2012
First Submitted That Met QC Criteria
January 18, 2012
First Posted (Estimate)
January 19, 2012
Study Record Updates
Last Update Posted (Estimate)
September 23, 2015
Last Update Submitted That Met QC Criteria
September 21, 2015
Last Verified
September 1, 2015
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- fr-HE530-01
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Prostate Cancer
-
Roswell Park Cancer InstituteRecruitingObesity | Overweight | Cancer Survivor | Prostate Adenocarcinoma | Stage I Prostate Cancer | Stage II Prostate Cancer | Stage III Prostate Cancer | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate Cancer | Stage IVA Prostate Cancer | Stage IVB Prostate Cancer | Stage A Prostate Cancer | Stage... and other conditionsUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Regeneron Pharmaceuticals; Prostate Cancer FoundationWithdrawnStage III Prostate Cancer | Stage IV Prostate Cancer | Stage IVA Prostate Cancer | Stage IVB Prostate Cancer | Stage IIIA Prostate Cancer | Stage IIIB Prostate Cancer | Stage IIIC Prostate Cancer
-
University of Southern CaliforniaNational Cancer Institute (NCI); SanofiTerminatedDiarrhea | Recurrent Prostate Cancer | Hormone-resistant Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
Jonsson Comprehensive Cancer CenterProgenics Pharmaceuticals, Inc.TerminatedRandomized Trial of PSMA PET Scan Before Definitive Radiation Therapy for Prostate Cancer (PSMA-dRT)Stage II Prostate Cancer AJCC v8 | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IIA Prostate Cancer AJCC v8 | Stage IIB Prostate Cancer AJCC v8 | Stage I Prostate...United States
-
Jonsson Comprehensive Cancer CenterNational Cancer Institute (NCI)CompletedRecurrent Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
Ryan Kohlbrenner, MDRadiological Society of North AmericaCompletedProstate Adenocarcinoma | Stage IV Prostate Cancer AJCC v8 | Prostate Carcinoma | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IVA Prostate Cancer AJCC v8 | Stage...United States
-
Ohio State University Comprehensive Cancer CenterRiverside Methodist HospitalCompletedStage I Prostate Cancer | Stage III Prostate Cancer | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
University of California, IrvineCompletedRecurrent Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Adenocarcinoma of the Prostate | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
Mayo ClinicNational Cancer Institute (NCI)WithdrawnStage I Prostate Cancer AJCC v8 | Stage II Prostate Cancer AJCC v8 | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IIA Prostate Cancer AJCC v8 | Stage IIB Prostate...United States
-
Barbara Ann Karmanos Cancer InstituteGenentech, Inc.CompletedRecurrent Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Adenocarcinoma of the Prostate | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
Clinical Trials on ELIGARD 22.5mg
-
Weill Medical College of Cornell UniversityNational Institute on Aging (NIA); Tolmar PharmaceuticalsRecruitingAlzheimer Disease | Mild Cognitive ImpairmentUnited States
-
National Taiwan University HospitalDebiopharm International SA; Ministry of Health and WelfareNot yet recruitingTriple Negative Breast Cancer | Premenopausal Breast Cancer
-
Juravinski Cancer CenterSanofiUnknown
-
Astellas Pharma Singapore Pte. Ltd.CompletedProstate CancerHong Kong, Indonesia, Malaysia, Philippines, Singapore, Taiwan, Thailand, Vietnam
-
McGill University Health Centre/Research Institute...SanofiRecruitingProstate CancerCanada
-
Institut Cancerologie de l'OuestAstellas Pharma IncActive, not recruiting
-
UNICANCERAstellas Pharma IncActive, not recruiting
-
Astellas Pharma IncCompletedProstate CancerBelgium, France, Spain, Italy, Hungary, Russian Federation, Germany, Slovakia, Finland, Czech Republic
-
Chesapeake Urology Research AssociatesSanofi-SynthelaboCompleted
-
Astellas Pharma Europe Ltd.Terminated